BioCentury
ARTICLE | Financial News

Atreca raises $35M in series B

August 17, 2017 7:03 PM UTC

Cancer immunotherapy company Atreca Inc. (Redwood City, Calif.) raised $35 million in a series B round co-led by new investor Wellington Management and an undisclosed U.S. healthcare fund, which is an existing investor. New investor Cormorant Asset Management participated as did other new and existing investors.

The company has a library of more than 400 patient-derived antibodies based on its Immune Repertoire Capture single-cell analysis technology, which originated at Stanford University. The platform generates full-length, natively paired heavy and light chain variable region sequences of a patient's antibody and T cell repertoires, and also detects levels of co-expressed genes that reveal cell subtype and phenotype. ...